Several states are reporting cases of measles, a highly contagious viral disease. Both children and adults can get measles.

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune ...

Older adults with cancer respond just as well as younger patients to immune checkpoint inhibitors despite age-related immune system differences ...

Moreover, the panelists emphasized that real-world evidence goes beyond clinical trial data. It involves continuous patient ...

New Phase II data demonstrate amlitelimab’s efficacy in heterogeneous inflammatory asthma, as lunsekimig and itepekimab ...

Sanofi is continuing to splash the cash for autoimmune and immunology assets this spring by penning a new deal with ...

A drug billed by Sanofi as a successor to its blockbuster inflammation and immunology blockbuster Dupixent is being prepared ...

The startup, affiliated with China-based antibody designer Helixon Therapeutics, is developing bispecific drugs aimed at ...

Earendil Labs, a US AI-driven R&D next-generation biologics therapeutics start-up, has entered into a license agreement with French pharma major Sanofi (Euronext: SAN) for two potential first-in-class ...

Hoechst and Rhône-Poulenc Rorer were the two companies that merged to form Aventis. Despite Sanofi-Synthélabo’s size, the company found itself forced to partner with larger pharmaceutical ...

On its way to generating sales of $14 billion in just its seventh full year on the market, Sanofi and Regeneron’s Dupixent has experienced few setbacks. One came in 2023, however, when the FDA ...

French pharma major Sanofi (Euronext: SAN) has shared new progress from its mid- to late-stage respiratory pipeline. The Paris-based company has presented new Phase II data on amlitelimab, showing its ...